Clinical trial
SANTORINI-MX: Lipid Management Gaps in Mexican Patients at High and Very High Cardiovascular Risk
NCT07930975 is registered in ClinicalTrials.gov with Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- SANTORINI-MX: Lipid Management Gaps in Mexican Patients at High and Very High Cardiovascular Risk
- Lead sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- January 1, 2027
- Completion date
- February 28, 2029
- Enrollment
- 1,600 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
Arms
As registered; 1 arm.
-
High and Very High Cardiovascular Risk Patients
Adults aged 18 years or older classified as having high or very high cardiovascular risk according to the 2019 ESC/EAS guidelines, who are receiving or have a clinical indication for lipid-lowering therapy. Participants will be consecutively enrolled at participating healthcare centers in Mexico and assessed at baseline and after 12 ± 2 months. Lipid levels, cardiovascular risk factors, lipid-lowering treatments, treatment intensification, medication adherence, and barriers to optimal lipid management will be recorded. All treatments will be prescribed according to routine clinical practice, without protocol-assigned interventions.
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Proportion of Participants Achieving Risk-Based LDL-C Treatment Goals
The percentage of participants achieving low-density lipoprotein cholesterol (LDL-C) targets according to their cardiovascular risk category, as defined by the 2019 ESC/EAS guidelines: LDL-C below 70 mg/dL for high-risk participants and below 55 mg/dL for very-high-risk participants. The numerator will be the number of participants achieving their corresponding risk-based LDL-C target, and the denominator will be the number of evaluable participants with baseline LDL-C data. Results will be reported overall and stratified by cardiovascular risk category, with 95% confidence intervals.
Lead sponsor's other trials
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, most recent start first.
+155 more trials See the organization page
Similar trials
Same condition (Hypercholesterolemia) and phase, most recent start first.
+158 more trials See the condition page